- Successful first implantation case with advanced bone graft material
- Entry into biggest orthopedics market worldwide
Kleinostheim, Germany/Research Triangle Park, USA, 11 May 2017 - curasan Inc., the US-subsidiary of curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of orthobiologics, today announced the first implantation of their CERASORB(R) Ortho Foam advanced bone graft product signaling curasan's entrance in the US orthopedics market. The United States orthopedics market, specifically for bone grafting products, is the largest market globally with annual market potential of over $800 million USD.
CERASORB(R) Ortho Foam was used in a challenging knee arthrodesis case performed by Dr. Divakar Krishnareddy at Los Angeles Community Hospital in Los Angeles, California. Dr. Krishnareddy commented on the product: "It's exciting to see a product that has both excellent handling and strong clinical evidence become available in the USA. CERASORB(R) Ortho Foam's handling is very easy to adapt to underlying anatomy while preventing leaving large gaps allowing graft placement where you need it."
"curasan has a strong 20 plus year history of delivering novel and highly effective materials for the bone regeneration market. With numerous patents, peer-reviewed clinical studies, and robust on-going research and development and clinical programs, we provide cost-effective and clinically proven orthobiologic solutions that integrate seamlessly in the operating room," said M. Shane Ray, President of curasan, Inc. "We are excited at entering the orthopedic market here in the United States and look forward to working with our sales partners to provide advanced biomaterials to our surgeon customers throughout the USA".
About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in the Research Triangle Park area, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.
Head of Investor Relations
Tel. +49 6027 40900-45
Fax +49 6027 40900-39
Head of Corporate Communications
Tel. +49 6027 40900-51
Fax +49 6027 40900-39
Published at Yahoo Finance News